Supplementary Figure S2 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib Article Swipe
Miro J. Eigenmann
,
Nicolas Frances
,
Gerhard Hoffmann
,
Thierry Lavé
,
Antje‐Christine Walz
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1158/1535-7163.22508388
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1158/1535-7163.22508388
Graphs displaying plasma PK profile of the long term and short term experiments for erlotinib and gefitinib.
Related Topics
Concepts
Metadata
- Type
- preprint
- Language
- en
- Landing Page
- https://doi.org/10.1158/1535-7163.22508388
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4362528217
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4362528217Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1158/1535-7163.22508388Digital Object Identifier
- Title
-
Supplementary Figure S2 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and GefitinibWork title
- Type
-
preprintOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-04-03Full publication date if available
- Authors
-
Miro J. Eigenmann, Nicolas Frances, Gerhard Hoffmann, Thierry Lavé, Antje‐Christine WalzList of authors in order
- Landing page
-
https://doi.org/10.1158/1535-7163.22508388Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1158/1535-7163.22508388Direct OA link when available
- Concepts
-
Erlotinib, Gefitinib, Term (time), Pharmacology, Medicine, Oncology, Epidermal growth factor receptor, Internal medicine, Physics, Receptor, Quantum mechanicsTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4362528217 |
|---|---|
| doi | https://doi.org/10.1158/1535-7163.22508388 |
| ids.doi | https://doi.org/10.1158/1535-7163.22508388 |
| ids.openalex | https://openalex.org/W4362528217 |
| fwci | 0.0 |
| type | preprint |
| title | Supplementary Figure S2 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10417 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9965999722480774 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2740 |
| topics[0].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[0].display_name | Lung Cancer Treatments and Mutations |
| topics[1].id | https://openalex.org/T11157 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9943000078201294 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2716 |
| topics[1].subfield.display_name | Genetics |
| topics[1].display_name | Chronic Lymphocytic Leukemia Research |
| topics[2].id | https://openalex.org/T10231 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9894999861717224 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2730 |
| topics[2].subfield.display_name | Oncology |
| topics[2].display_name | Pancreatic and Hepatic Oncology Research |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2778087573 |
| concepts[0].level | 4 |
| concepts[0].score | 0.942672610282898 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q418369 |
| concepts[0].display_name | Erlotinib |
| concepts[1].id | https://openalex.org/C2780580887 |
| concepts[1].level | 4 |
| concepts[1].score | 0.9376739263534546 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q417824 |
| concepts[1].display_name | Gefitinib |
| concepts[2].id | https://openalex.org/C61797465 |
| concepts[2].level | 2 |
| concepts[2].score | 0.4675145745277405 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q1188986 |
| concepts[2].display_name | Term (time) |
| concepts[3].id | https://openalex.org/C98274493 |
| concepts[3].level | 1 |
| concepts[3].score | 0.46675992012023926 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[3].display_name | Pharmacology |
| concepts[4].id | https://openalex.org/C71924100 |
| concepts[4].level | 0 |
| concepts[4].score | 0.37993496656417847 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[4].display_name | Medicine |
| concepts[5].id | https://openalex.org/C143998085 |
| concepts[5].level | 1 |
| concepts[5].score | 0.3643653094768524 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[5].display_name | Oncology |
| concepts[6].id | https://openalex.org/C2779438470 |
| concepts[6].level | 3 |
| concepts[6].score | 0.314869225025177 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q424401 |
| concepts[6].display_name | Epidermal growth factor receptor |
| concepts[7].id | https://openalex.org/C126322002 |
| concepts[7].level | 1 |
| concepts[7].score | 0.28107962012290955 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[7].display_name | Internal medicine |
| concepts[8].id | https://openalex.org/C121332964 |
| concepts[8].level | 0 |
| concepts[8].score | 0.21660500764846802 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q413 |
| concepts[8].display_name | Physics |
| concepts[9].id | https://openalex.org/C170493617 |
| concepts[9].level | 2 |
| concepts[9].score | 0.1193968653678894 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q208467 |
| concepts[9].display_name | Receptor |
| concepts[10].id | https://openalex.org/C62520636 |
| concepts[10].level | 1 |
| concepts[10].score | 0.0 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q944 |
| concepts[10].display_name | Quantum mechanics |
| keywords[0].id | https://openalex.org/keywords/erlotinib |
| keywords[0].score | 0.942672610282898 |
| keywords[0].display_name | Erlotinib |
| keywords[1].id | https://openalex.org/keywords/gefitinib |
| keywords[1].score | 0.9376739263534546 |
| keywords[1].display_name | Gefitinib |
| keywords[2].id | https://openalex.org/keywords/term |
| keywords[2].score | 0.4675145745277405 |
| keywords[2].display_name | Term (time) |
| keywords[3].id | https://openalex.org/keywords/pharmacology |
| keywords[3].score | 0.46675992012023926 |
| keywords[3].display_name | Pharmacology |
| keywords[4].id | https://openalex.org/keywords/medicine |
| keywords[4].score | 0.37993496656417847 |
| keywords[4].display_name | Medicine |
| keywords[5].id | https://openalex.org/keywords/oncology |
| keywords[5].score | 0.3643653094768524 |
| keywords[5].display_name | Oncology |
| keywords[6].id | https://openalex.org/keywords/epidermal-growth-factor-receptor |
| keywords[6].score | 0.314869225025177 |
| keywords[6].display_name | Epidermal growth factor receptor |
| keywords[7].id | https://openalex.org/keywords/internal-medicine |
| keywords[7].score | 0.28107962012290955 |
| keywords[7].display_name | Internal medicine |
| keywords[8].id | https://openalex.org/keywords/physics |
| keywords[8].score | 0.21660500764846802 |
| keywords[8].display_name | Physics |
| keywords[9].id | https://openalex.org/keywords/receptor |
| keywords[9].score | 0.1193968653678894 |
| keywords[9].display_name | Receptor |
| language | en |
| locations[0].id | doi:10.1158/1535-7163.22508388 |
| locations[0].is_oa | True |
| locations[0].source | |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.1158/1535-7163.22508388 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5023517315 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-7193-9264 |
| authorships[0].author.display_name | Miro J. Eigenmann |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Miro J. Eigenmann |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5052927788 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Nicolas Frances |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Nicolas Frances |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5111616260 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Gerhard Hoffmann |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Gerhard Hoffmann |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5044090708 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Thierry Lavé |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Thierry Lavé |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5078439299 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-2177-545X |
| authorships[4].author.display_name | Antje‐Christine Walz |
| authorships[4].author_position | last |
| authorships[4].raw_author_name | Antje-Christine Walz |
| authorships[4].is_corresponding | False |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1158/1535-7163.22508388 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Supplementary Figure S2 from Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10417 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9965999722480774 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2740 |
| primary_topic.subfield.display_name | Pulmonary and Respiratory Medicine |
| primary_topic.display_name | Lung Cancer Treatments and Mutations |
| related_works | https://openalex.org/W2254126652, https://openalex.org/W2418692205, https://openalex.org/W2015104488, https://openalex.org/W3147989365, https://openalex.org/W2280113021, https://openalex.org/W2408927976, https://openalex.org/W2348666640, https://openalex.org/W2363852307, https://openalex.org/W2184487997, https://openalex.org/W2168841302 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1158/1535-7163.22508388 |
| best_oa_location.is_oa | True |
| best_oa_location.source | |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.1158/1535-7163.22508388 |
| primary_location.id | doi:10.1158/1535-7163.22508388 |
| primary_location.is_oa | True |
| primary_location.source | |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.1158/1535-7163.22508388 |
| publication_date | 2023-04-03 |
| publication_year | 2023 |
| referenced_works_count | 0 |
| abstract_inverted_index.PK | 3 |
| abstract_inverted_index.of | 5 |
| abstract_inverted_index.and | 9, 15 |
| abstract_inverted_index.for | 13 |
| abstract_inverted_index.the | 6 |
| abstract_inverted_index.long | 7 |
| abstract_inverted_index.term | 8, 11 |
| abstract_inverted_index.short | 10 |
| abstract_inverted_index.plasma | 2 |
| abstract_inverted_index.profile | 4 |
| abstract_inverted_index.erlotinib | 14 |
| abstract_inverted_index.displaying | 1 |
| abstract_inverted_index.experiments | 12 |
| abstract_inverted_index.<p>Graphs | 0 |
| abstract_inverted_index.gefitinib.</p> | 16 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 5 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/9 |
| sustainable_development_goals[0].score | 0.44999998807907104 |
| sustainable_development_goals[0].display_name | Industry, innovation and infrastructure |
| citation_normalized_percentile.value | 0.17856888 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |